Strike Pharma
Strike Pharma is a Swedish biotech company developing in vivo CAR-T therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery. Founded in 2020, it leverages scientific discoveries from Uppsala University and SciLifeLab, with main investors including Eir Ventures, Flerie Invest, Almi Invest, AB Ility, and Monesi Förvaltnings AB. The company's mission is to enable targeted nanoparticle delivery for innovative immunotherapies, aiming to improve treatment options for autoimmune diseases and cancers.
Industries
Nr. of Employees
small (1-50)
Strike Pharma
Strike Pharma, SmiLe Venture Hub, Scheeletorget 1, Medicon Village, 223 81 Lund, Sweden
Products
Affinity-based targeted delivery platform for nanoparticles
A platform combining a short peptide tag attached to payloads (including LNPs) and scFv-linked targeting units to enable modular, high-affinity, cell-specific delivery of diverse payloads (peptides, RNA, oligonucleotides).
Lead preclinical in vivo CAR-T candidate targeting B cells
A preclinical candidate consisting of T-cell-directed LNPs carrying CAR-encoding mRNA, combined with a bispecific targeting antibody that delivers the LNP to T cells to generate B-cell-targeting CAR-Ts in vivo; intended for B-cell-dependent autoimmune disease and oncology indications.
Affinity-based targeted delivery platform for nanoparticles
A platform combining a short peptide tag attached to payloads (including LNPs) and scFv-linked targeting units to enable modular, high-affinity, cell-specific delivery of diverse payloads (peptides, RNA, oligonucleotides).
Lead preclinical in vivo CAR-T candidate targeting B cells
A preclinical candidate consisting of T-cell-directed LNPs carrying CAR-encoding mRNA, combined with a bispecific targeting antibody that delivers the LNP to T cells to generate B-cell-targeting CAR-Ts in vivo; intended for B-cell-dependent autoimmune disease and oncology indications.
Services
Joint projects and agreements with academic and industry partners for platform validation, cell line development, and candidate advancement.
Joint projects and agreements with academic and industry partners for platform validation, cell line development, and candidate advancement.
Expertise Areas
- In vivo CAR-T development
- Targeted nanoparticle delivery
- Bispecific antibody engineering
- Peptide cargo delivery and vaccine-style antigen presentation
Key Technologies
- Lipid nanoparticle (LNP) delivery
- mRNA therapeutics (non-viral delivery)
- Affinity tag–scFv conjugation platform
- Bispecific antibody formats
News & Updates
Strike Pharma presented further developments at CICON23 on September 24, 2023.
Strike Pharma presented latest developments at AACR 2023 on April 18, 2023.
On May 2, 2022, Strike Pharma, Uppsala University, and KTH Royal Institute of Technology presented at CIMT 2022.
On February 4, 2025, Per Norlén joined Strike Pharma as the new CEO.
On July 4, 2024, Strike Pharma was granted a patent in Japan to protect its core ADAC technology.
On July 4, 2024, Strike Pharma received funding from the BIO-X Accelerate program.
Strike Pharma presented further developments at CICON23 on September 24, 2023.
Strike Pharma presented latest developments at AACR 2023 on April 18, 2023.
On May 2, 2022, Strike Pharma, Uppsala University, and KTH Royal Institute of Technology presented at CIMT 2022.
On February 4, 2025, Per Norlén joined Strike Pharma as the new CEO.
On July 4, 2024, Strike Pharma was granted a patent in Japan to protect its core ADAC technology.
On July 4, 2024, Strike Pharma received funding from the BIO-X Accelerate program.